Cardiovascular disease

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

Retrieved on: 
понедельник, июня 3, 2024
Health, Plaque, CMS, CGS, Patient, WPS, Senior, Policy, NGS, FDA, LCD, Macs, Cardiovascular disease, Pharmaceutical industry

Five Medicare Administrative Contractors (MACs), CGS, NGS, Noridian, Palmetto GBA, and WPS, released draft Local Coverage Determinations (LCD) for Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA ).

Key Points: 
  • Five Medicare Administrative Contractors (MACs), CGS, NGS, Noridian, Palmetto GBA, and WPS, released draft Local Coverage Determinations (LCD) for Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA ).
  • Leveraging our expertise and proven success creating new AI reimbursement categories as done with HeartFlow FFRCT, similar coverage and adoption for Plaque Analysis is anticipated, ensuring it becomes an integral part of coronary care.
  • “We are excited about this milestone, as it highlights the critical importance of accurately quantifying plaque in cardiovascular disease management,” said John Farquhar, chief executive officer at HeartFlow.
  • “We are confident that Plaque Analysis will not only meet but exceed the rigorous standards of Medicare,” added Cara Santillo, Senior Vice President of Market Access and Reimbursement at HeartFlow.

Cannabis Beverages Global Strategic Business Report 2024-2030: Alcoholic Beverage Companies Seek Role in the $3.8 Billion Market - ResearchAndMarkets.com

Retrieved on: 
понедельник, июня 3, 2024
Retail, Natural Resources, Cannabis, Food, Beverage, Central Statistics Office (India), Development, Fatality, Stroke, Developed country, Cardiovascular disease, Drug

World Cannabis Beverages Market by Type (2024 & 2030): Percentage Breakdown of Value Sales for Non-Alcoholic, and Alcoholic

Key Points: 
  • World Cannabis Beverages Market by Type (2024 & 2030): Percentage Breakdown of Value Sales for Non-Alcoholic, and Alcoholic
    Global Market for Cannabis Beverages: Percentage Breakdown of Sales for Developed and Developing Regions (2024 & 2030)
    Global Market for Cannabis Beverages - Geographic Regions Ranked by % CAGR (Sales) for 2023-2030: USA, Canada, Europe, Asia-Pacific, and Rest of World
    World Population (in Thousands) by Geographic Region for the Years 2018, 2025, 2040, 2050
    World Diabetes and Population Statistics (2019, 2030 & 2045)
    Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

What’s the difference between vegan and vegetarian?

Retrieved on: 
понедельник, июня 3, 2024
Well, Blood pressure, Mineral, Cat, Vegetarianism, Seafood, Diabetes, National Health, Stroke, Diet, Animal, Cancer, Iron, Vegetable, Meat, Health, Wool, Risk, Iodine, OVO, Poultry, Vitamin D, Veganism, Nutrient, Thought, Fruit, Vitamin, Hypertension, Common, Meta-analysis, Calcium, Dementia, Medical Research Council, Soap, Motivation, Grain boundary strengthening, Cardiovascular disease, Honey

is a new editorial product that explains the similarities and differences between commonly confused health and medical terms, and why they matter.

Key Points: 
  • is a new editorial product that explains the similarities and differences between commonly confused health and medical terms, and why they matter.
  • Vegan and vegetarian diets are plant-based diets.

What’s a vegan diet?


A vegan diet is an entirely plant-based diet. It doesn’t include any meat and animal products. So, no meat, poultry, fish, seafood, eggs, dairy or honey.

What’s a vegetarian diet?

  • A vegetarian diet is a plant-based diet that generally excludes meat, poultry, fish and seafood, but can include animal products.
  • Well, it’s because there are variations on a vegetarian diet: a lacto-ovo vegetariandiet excludes meat, poultry, fish and seafood, but includes eggs, dairy and honey an ovo-vegetariandiet excludes meat, poultry, fish, seafood and dairy, but includes eggs and honey a lacto-vegetariandiet excludes meat, poultry, fish, seafood and eggs, but includes dairy and honey a pescatariandiet excludes meat and poultry, but includes eggs, dairy, honey, fish and seafood a flexitarian, or semi-vegetarian diet, includes eggs, dairy and honey and may include small amounts of meat, poultry, fish and seafood.

Are these diets healthy?

  • A 2023 review looked at the health effects of vegetarian and vegan diets from two types of study.
  • Observational studies followed people over the years to see how their diets were linked to their health.
  • It showed eating a vegetarian diet was associated with a systolic blood pressure (the first number in your blood pressure reading) an average 5 mmHg lower compared with non-vegetarian diets.
  • It seems vegetarian diets are more likely to be healthier, across a number of measures.

But it can be about more than just food

  • The motivation for following a vegan or vegetarian diet can vary from person to person.
  • And for many people who follow a vegan or vegetarian diet, this forms a central part of their identity.

So, should I adopt a vegan or vegetarian diet?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
пятница, мая 31, 2024
Cardiovascular disease, Employment, Therapy

BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received an aggregate of 23,600 restricted stock units (RSUs).
  • The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.

The Urology Care Foundation Encourages Men to Take Charge of Their Health, One Checkup at A Time, For Men’s Health Month

Retrieved on: 
пятница, мая 31, 2024
Peyronie's disease, Disease, Diabetes, Cardiovascular disease, American Urological Association, UCHealth, AUA, Urology, Prostate cancer, Diagnosis, Male, Testosterone, Health, Life, Cancer, Testicular cancer, Vasectomy, Semen analysis, Education minister, Erectile dysfunction, Infertility, BPH, System, Incontinence

BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.

Key Points: 
  • BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.
  • But cancers are not the only urological issues men should be getting checked out; for men, urology includes the entire urinary tract and reproductive organs.
  • Once these problems are diagnosed, men can partner with a men's health specialist to get things back on the right track.
  • For more information on all aspects of men’s health, view the Urology Care Foundation’s Men’s Health Month Info Center.

Verve Therapeutics Announces Leadership Update

Retrieved on: 
пятница, мая 31, 2024
Patient, Cardiovascular disease, Scripps Research, Biomedical Research, Therapy, Verve, Research, CSO, Drug discovery, Organic chemistry, AstraZeneca, Flinders University, Pharmaceutical industry

BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been appointed chief scientific officer (CSO), effective June 21, 2024. Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.

Key Points: 
  • Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.
  • “Over the past two years, Troy has been a respected colleague and wonderful leader at Verve, preceded by a longstanding career in research and development and program and portfolio management.
  • Prior to joining Verve, he served as senior vice president of research and development at Spero Therapeutics, where he helped build the research and development organization and led multiple programs into first-in-human studies and through early clinical development.
  • Dr. Lister has also held scientific and leadership roles at the Novartis Institutes for Biomedical Research and AstraZeneca.

Verve Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
четверг, мая 30, 2024
Conference, Cardiovascular disease, Therapy

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during the following investor conferences:

Key Points: 
  • BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during the following investor conferences:
    Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1 p.m.
  • ET in New York, NY
    Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 8 a.m.
  • ET in Miami Beach, FL
    Live webcasts will be available in the investor section of the company's website at www.vervetx.com , and will be archived for 30 days following the fireside chats.

Global Heart Valves Industry Forecast to 2028: Investments in Innovative Technologies Enable Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
пятница, мая 31, 2024
Health, Cardiology, Heart, Traction, Percutaneous aortic valve replacement, Cardiovascular disease, TAVR

The "Global Heart Valves Industry - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Heart Valves Industry - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • This report covers the heart valves industry, including aortic, mitral, tricuspid, and pulmonary valves.
  • The report addresses critical questions such as market sizes, growth rates, opportunities, strategic imperatives, technology impact, and untapped potential in the industry.
  • The industry is growing rapidly in Asia-Pacific because of the high number of people suffering from heart valve diseases and growing awareness and accessibility to heart valve technologies.

Johnson & Johnson Completes Acquisition of Shockwave Medical

Retrieved on: 
пятница, мая 31, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Cardiology, Patient, Cardiovascular disease, JNJ, Abiomed, Coronary artery disease, CAD, PAD, Johnson & Johnson, Peripheral artery disease, Death, Electrophysiology, Acquisition, Shock wave, Medtech, IVL, Worldwide, Pharmaceutical industry

Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.

Key Points: 
  • Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
  • Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
  • We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.”
    Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.

New Study Findings Show Statistically Significant Weight Loss for Medicare-Eligible Population in the Wondr Program

Retrieved on: 
среда, мая 29, 2024
Diabetes, Cardiovascular disease, Doctor of Philosophy, Medicare, Obesity, University, Overweight, Male, Health, Frontiers Media, Research, Cancer, Weight loss, FACSM, Curriculum, Frailty, Deficit spending, Quality of life, Female, Dietary supplement

“This study demonstrates that Wondr can be used to engage older populations in weight loss,” said Renee Rogers, PhD, FACSM, lead author, senior scientist, University of Kansas Medical Center, and Wondr Health instructor.

Key Points: 
  • “This study demonstrates that Wondr can be used to engage older populations in weight loss,” said Renee Rogers, PhD, FACSM, lead author, senior scientist, University of Kansas Medical Center, and Wondr Health instructor.
  • The purpose of this study was to evaluate Wondr as a more accessible digital intervention for weight loss in older adults.
  • The average weight loss was statistically significant at nearly 7 pounds at 15.5 weeks.
  • Weight loss was significantly greater in male (8.36 pounds) versus female participants (6.33 pounds), and a longer engagement in the program was associated with greater weight loss.